Literature DB >> 31002271

Quantitative proteomic analysis of venom from Southern India common krait (Bungarus caeruleus) and identification of poorly immunogenic toxins by immune-profiling against commercial antivenom.

Aparup Patra1, Abhishek Chanda1, Ashis K Mukherjee1.   

Abstract

OBJECTIVES: To study the venom proteome composition of Southern India (SI) Common Krait (Bungarus caeruleus) and immunological cross-reactivity between venom against commercial antivenom.
METHODS: Proteomic analysis was done by nano LC-MS/MS and toxins were quantitated by label-free analysis. The immunological cross-reactivity of venom towards polyvalent antivenom (PAV) was assessed by ELISA, Immunoblotting, and immuno-chromatographic methods.
RESULTS: A total of 57 enzymatic and non-enzymatic proteins belonging to 12 snake venom protein families were identified. The three finger toxins (3FTx) (48.3%) and phospholipase A2 (PLA2) (37.6%) represented the most abundant non-enzymatic and enzymatic proteins, respectively. β-bungarotoxin (12.9%), a presynaptic neurotoxin, was also identified. The venom proteome composition is well correlated with its enzymatic activities, reported pharmacological properties, and clinical manifestations of krait envenomation. Immuno-cross-reactivity studies demonstrated better recognition of high molecular weight proteins (>45 kDa) of this venom by PAVs compared to low molecular weight (<15 kDa) toxins such as PLA2 and 3FTxs.
CONCLUSION: The poor recognition of <15 kDa mass SI B. caeruleus venom proteins is of grave concern for the successful treatment of krait envenomation. Therefore, emphasis should be given to improve the immunization protocols and/or supplement of antibodies raised specifically against the <15 kDa toxins of this venom.

Entities:  

Keywords:  ESI-LC MS/MS; krait venom; pre-synaptic neurotoxin; snakebite; venom proteome; venom–antivenom cross-reactivity

Mesh:

Substances:

Year:  2019        PMID: 31002271     DOI: 10.1080/14789450.2019.1609945

Source DB:  PubMed          Journal:  Expert Rev Proteomics        ISSN: 1478-9450            Impact factor:   3.940


  6 in total

1.  Oxidative stress and antioxidant defense in detoxification systems of snake venom-induced toxicity.

Authors:  Degang Dong; Zhongping Deng; Zhangren Yan; Wenli Mao; Jun Yi; Mei Song; Qiang Li; Jun Chen; Qi Chen; Liang Liu; Xi Wang; Xiuqin Huang; Wanchun Wang
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2020-10-19

Review 2.  Evolution Bites - Timeworn Inefficacious Snakebite Therapy in the Era of Recombinant Vaccines.

Authors:  Navneet Kaur; Ashwin Iyer; Kartik Sunagar
Journal:  Indian Pediatr       Date:  2021-03-15       Impact factor: 1.411

3.  Beyond the 'big four': Venom profiling of the medically important yet neglected Indian snakes reveals disturbing antivenom deficiencies.

Authors:  R R Senji Laxme; Suyog Khochare; Hugo Francisco de Souza; Bharat Ahuja; Vivek Suranse; Gerard Martin; Romulus Whitaker; Kartik Sunagar
Journal:  PLoS Negl Trop Dis       Date:  2019-12-05

4.  A Wolf in Another Wolf's Clothing: Post-Genomic Regulation Dictates Venom Profiles of Medically-Important Cryptic Kraits in India.

Authors:  Kartik Sunagar; Suyog Khochare; R R Senji Laxme; Saurabh Attarde; Paulomi Dam; Vivek Suranse; Anil Khaire; Gerard Martin; Ashok Captain
Journal:  Toxins (Basel)       Date:  2021-01-19       Impact factor: 4.546

5.  Variations in neurotoxicity and proteome profile of Malayan krait (Bungarus candidus) venoms.

Authors:  Muhamad Rusdi Ahmad Rusmili; Iekhsan Othman; Syafiq Asnawi Zainal Abidin; Fathin Athirah Yusof; Kavi Ratanabanangkoon; Lawan Chanhome; Wayne C Hodgson; Janeyuth Chaisakul
Journal:  PLoS One       Date:  2019-12-30       Impact factor: 3.240

6.  Assessment of quality and pre-clinical efficacy of a newly developed polyvalent antivenom against the medically important snakes of Sri Lanka.

Authors:  Aparup Patra; Bhargab Kalita; Milind V Khadilkar; Nitin C Salvi; Pravin V Shelke; Ashis K Mukherjee
Journal:  Sci Rep       Date:  2021-09-14       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.